- Recruiting
NCT01665794: Phase 1/2: Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With RRMM
Updated: Jun 22, 2022
NCT01665794: Phase 1/2: Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
KPd
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT01665794
Sponsor:
University of Chicago
Collaborators:
National Cancer Institute (NCI)
Multiple Myeloma Research Foundation
MMRF
The study will investigate the effects of adding carfilzomib to the combination of pomalidomide and dexamethasone in sequential dose escalation cohorts in patients with relapsed or refractory multiple myeloma. This portion of the study is complete.
This study will also investigate the effects of adding daratumumab to the combination of carfilzomib, pomalidomide and dexamethasone.
ClinicalTrials.gov Identifier: NCT01464034
Official Title: Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment With Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
First Posted: August 15, 2012
Drug: Pomalidomide
Drug: Carfilzomib
Drug: dexamethasone
Drug: Daratumumab
Locations
United States, Illinois
United States, Michigan
United States, Tennessee
Canada, Ontario